{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:40:25Z","timestamp":1781023225337,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi del Piemonte Orientale Amedeo Avogrado"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recent data have suggested that insulin-requiring diabetes mostly contributes to the overall increase of thromboembolic risk in patients with atrial fibrillation (AF) on warfarin. We evaluated the prognostic role of a different diabetes status on clinical outcome in a large cohort of AF patients treated with edoxaban.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We accessed individual patients\u2019 data from the prospective, multicenter, ETNA-AF Europe Registry. We compared the rates of ischemic stroke\/transient ischemic attack (TIA)\/systemic embolism, myocardial infarction (MI), major bleeding and all-cause death at 2\u00a0years according to diabetes status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of an overall population of 13,133 patients, 2885 had diabetes (22.0%), 605 of whom (21.0%) were on insulin. The yearly incidence of ischemic stroke\/TIA\/systemic embolism was 0.86% in patients without diabetes, 0.87% in diabetic patients not receiving insulin (<jats:italic>p<\/jats:italic>\u2009=\u20090.92 vs no diabetes) and 1.81% in those on insulin (<jats:italic>p<\/jats:italic>\u2009=\u20090.002 vs no diabetes; p\u2009=\u20090.014 vs diabetes not on insulin). The annual rates of MI and major bleeding were 0.40%, 0.43%, 1.04% and 0.90%, 1.10% and 1.71%, respectively. All-cause yearly mortality was 3.36%, 5.02% and 8.91%. At multivariate analysis, diabetes on insulin was associated with a higher rate of ischemic stroke\/TIA\/systemic embolism [adjusted HR 2.20, 95% CI 1.37\u20133.54, <jats:italic>p<\/jats:italic>\u2009=\u20090.0011 vs no diabetes\u2009+\u2009diabetes not on insulin] and all-cause death [aHR 2.13 (95% CI 1.68\u20132.68, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001 vs no diabetes]. Diabetic patients not on insulin had a higher mortality [aHR 1.32 (1.11\u20131.57), <jats:italic>p<\/jats:italic>\u2009=\u20090.0015], but similar incidence of stroke\/TIA\/systemic embolism, MI and major bleeding, vs those without diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In a real-world cohort of AF patients on edoxaban, diabetes requiring insulin therapy, rather than the presence of diabetes per se, appears to be an independent factor affecting the occurrence of thromboembolic events during follow-up. Regardless of the diabetes type, diabetic patients had a lower survival compared with those without diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00392-022-02080-5","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T10:04:02Z","timestamp":1660730642000},"page":"1517-1528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry"],"prefix":"10.1007","volume":"112","author":[{"given":"Giuseppe","family":"Patti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Pecen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Casalnuovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius Constantin","family":"Manu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"2080_CR1","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","volume":"285","author":"BF Gage","year":"2001","unstructured":"Gage BF, Waterman AD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864. https:\/\/doi.org\/10.1001\/jama.285.22.2864","journal-title":"JAMA"},{"key":"2080_CR2","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"AJ Camm","year":"2010","unstructured":"Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369\u20132429. https:\/\/doi.org\/10.1093\/eurheartj\/ehq278","journal-title":"Eur Heart J"},{"key":"2080_CR3","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","volume":"33","author":"AJ Camm","year":"2012","unstructured":"Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines (CPG) (2012) 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J 33:2719\u20132747. https:\/\/doi.org\/10.1093\/eurheartj\/ehs253","journal-title":"Eur Heart J"},{"key":"2080_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42:373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612","journal-title":"Eur Heart J"},{"key":"2080_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jacc.2016.10.069","volume":"69","author":"G Patti","year":"2017","unstructured":"Patti G, Lucerna M, Cavallari I et al (2017) Insulin-requiring versus noninsulin-requiring diabetes and thromboembolic risk in patients with atrial fibrillation. J Am Coll Cardiol 69:409\u2013419. https:\/\/doi.org\/10.1016\/j.jacc.2016.10.069","journal-title":"J Am Coll Cardiol"},{"key":"2080_CR6","doi-asserted-by":"publisher","first-page":"058","DOI":"10.1055\/s-0030-1270072","volume":"37","author":"G Targher","year":"2011","unstructured":"Targher G, Chonchol M, Zoppini G, Franchini M (2011) Hemostatic disorders in type I diabetes mellitus. Semin Thromb Hemost 37:058\u2013065. https:\/\/doi.org\/10.1055\/s-0030-1270072","journal-title":"Semin Thromb Hemost"},{"key":"2080_CR7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.amjcard.2019.11.030","volume":"125","author":"G Patti","year":"2020","unstructured":"Patti G, Cerchiara E, Bressi E et al (2020) Endothelial dysfunction, fibrinolytic activity, and coagulation activity in patients with atrial fibrillation according to type II diabetes mellitus status. Am J Cardiol 125:751\u2013758. https:\/\/doi.org\/10.1016\/j.amjcard.2019.11.030","journal-title":"Am J Cardiol"},{"key":"2080_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/ehjcvp\/pvaa140","volume":"8","author":"R De Caterina","year":"2022","unstructured":"De Caterina R, Patti G, Westerbergh J et al (2022) Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the Aristotle trial. Eur Heart J-Cardiovasc Pharmacother 8:227\u2013235. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa140","journal-title":"Eur Heart J-Cardiovasc Pharmacother"},{"key":"2080_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2459\/JCM.0000000000000737","volume":"20","author":"R De Caterina","year":"2019","unstructured":"De Caterina R, Kelly P, Monteiro P et al (2019) Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. J Cardiovasc Med 20:97\u2013104. https:\/\/doi.org\/10.2459\/JCM.0000000000000737","journal-title":"J Cardiovasc Med"},{"key":"2080_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12872-019-1144-x","volume":"19","author":"R De Caterina","year":"2019","unstructured":"De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, Lopez-de-Sa E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Kerschnitzki M, Reimitz PE, Kirchhof P, On behalf of the ETNA-AF Europe investigators (2019) Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). BMC Cardiovasc Disord 19:165. https:\/\/doi.org\/10.1186\/s12872-019-1144-x","journal-title":"BMC Cardiovasc Disord"},{"key":"2080_CR11","doi-asserted-by":"publisher","first-page":"f30","DOI":"10.1093\/ehjcvp\/pvaa079","volume":"7","author":"JR de Groot","year":"2021","unstructured":"de Groot JR, Weiss TW, Kelly P et al (2021) Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-europe study. Eur Heart J-Cardiovasc Pharmaco 7:f30\u2013f39. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa079","journal-title":"Eur Heart J-Cardiovasc Pharmaco"},{"key":"2080_CR12","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"2080_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ijcard.2005.03.003","volume":"105","author":"GYH Lip","year":"2005","unstructured":"Lip GYH, Varughese GI (2005) Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. Int J Cardiol 105:319\u2013321. https:\/\/doi.org\/10.1016\/j.ijcard.2005.03.003","journal-title":"Int J Cardiol"},{"key":"2080_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41569-018-0080-2","volume":"16","author":"G Patti","year":"2019","unstructured":"Patti G, Cavallari I, Andreotti F et al (2019) Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol 16:113\u2013130. https:\/\/doi.org\/10.1038\/s41569-018-0080-2","journal-title":"Nat Rev Cardiol"},{"key":"2080_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.amjcard.2011.03.004","volume":"108","author":"RR Huxley","year":"2011","unstructured":"Huxley RR, Filion KB, Konety S, Alonso A (2011) Meta-analysis of cohort and case\u2013control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 108:56\u201362. https:\/\/doi.org\/10.1016\/j.amjcard.2011.03.004","journal-title":"Am J Cardiol"},{"key":"2080_CR16","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955\u2013962. https:\/\/doi.org\/10.1016\/S0140-6736(13)62343-0","journal-title":"Lancet"},{"key":"2080_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2876","volume":"33","author":"G Patti","year":"2017","unstructured":"Patti G, Di Gioia G, Cavallari I, Nenna A (2017) Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: a study-level meta-analysis of phase III randomized trials. Diabetes Metab Res Rev 33:e2876. https:\/\/doi.org\/10.1002\/dmrr.2876","journal-title":"Diabetes Metab Res Rev"},{"key":"2080_CR18","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.jacc.2007.05.049","volume":"50","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Bernardo E, Sabat\u00e9 M et al (2007) Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50:1541\u20131547. https:\/\/doi.org\/10.1016\/j.jacc.2007.05.049","journal-title":"J Am Coll Cardiol"},{"key":"2080_CR19","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2337\/diacare.16.8.1137","volume":"16","author":"CE Khawand","year":"1993","unstructured":"Khawand CE, Jamart J, Donckier J et al (1993) hemostasis variables in type I diabetic patients without demonstrable vascular complications. Diabetes Care 16:1137\u20131145. https:\/\/doi.org\/10.2337\/diacare.16.8.1137","journal-title":"Diabetes Care"},{"key":"2080_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/0049-3848(92)90068-L","volume":"67","author":"F Carmassi","year":"1992","unstructured":"Carmassi F, Morale M, Puccetti R et al (1992) Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 67:643\u2013654. https:\/\/doi.org\/10.1016\/0049-3848(92)90068-L","journal-title":"Thromb Res"},{"key":"2080_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/(SICI)1520-7560(199911\/12)15:6<405::AID-DMRR69>3.0.CO;2-H","volume":"15","author":"TA Elhadd","year":"1999","unstructured":"Elhadd TA, Kennedy G, Hill A et al (1999) Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with type 1 diabetes with no clinical vascular disease. Diabetes Metab Res Rev 15:405\u2013411. https:\/\/doi.org\/10.1002\/(SICI)1520-7560(199911\/12)15:6%3c405::AID-DMRR69%3e3.0.CO;2-H","journal-title":"Diabetes Metab Res Rev"},{"key":"2080_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.vph.2011.03.005","volume":"54","author":"R Madonna","year":"2011","unstructured":"Madonna R, De Caterina R (2011) Cellular and molecular mechanisms of vascular injury in diabetes\u2014Part I: pathways of vascular disease in diabetes. Vascul Pharmacol 54:68\u201374. https:\/\/doi.org\/10.1016\/j.vph.2011.03.005","journal-title":"Vascul Pharmacol"},{"key":"2080_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.vph.2011.03.007","volume":"54","author":"R Madonna","year":"2011","unstructured":"Madonna R, De Caterina R (2011) Cellular and molecular mechanisms of vascular injury in diabetes\u2014Part II: Cellular mechanisms and therapeutic targets. Vascul Pharmacol 54:75\u201379. https:\/\/doi.org\/10.1016\/j.vph.2011.03.007","journal-title":"Vascul Pharmacol"},{"key":"2080_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.amjcard.2013.02.046","volume":"112","author":"C Spadaccio","year":"2013","unstructured":"Spadaccio C, Patti G, De Marco F et al (2013) Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the prospective ARMYDA-AGEs study). Am J Cardiol 112:21\u201326. https:\/\/doi.org\/10.1016\/j.amjcard.2013.02.046","journal-title":"Am J Cardiol"},{"key":"2080_CR25","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/ejhf.1146","volume":"20","author":"F Cosmi","year":"2018","unstructured":"Cosmi F, Shen L, Magnoli M et al (2018) Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes: insulin treatment and prognosis in chronic hf. Eur J Heart Fail 20:888\u2013895. https:\/\/doi.org\/10.1002\/ejhf.1146","journal-title":"Eur J Heart Fail"},{"key":"2080_CR26","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/ejhf.1535","volume":"21","author":"L Shen","year":"2019","unstructured":"Shen L, R\u00f8rth R, Cosmi D et al (2019) Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. Eur J Heart Fail 21:974\u2013984. https:\/\/doi.org\/10.1002\/ejhf.1535","journal-title":"Eur J Heart Fail"},{"key":"2080_CR27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1161\/ATVBAHA.117.310291","volume":"38","author":"K Park","year":"2018","unstructured":"Park K, Li Q, Evcimen ND et al (2018) Exogenous insulin infusion can decrease atherosclerosis in diabetic rodents by improving lipids, inflammation, and endothelial function. ATVB 38:92\u2013101. https:\/\/doi.org\/10.1161\/ATVBAHA.117.310291","journal-title":"ATVB"},{"key":"2080_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"The ORIGIN Trial Investigators","year":"2012","unstructured":"The ORIGIN Trial Investigators (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319\u2013328. https:\/\/doi.org\/10.1056\/NEJMoa1203858","journal-title":"N Engl J Med"},{"key":"2080_CR29","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992. https:\/\/doi.org\/10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"2080_CR30","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2337\/dc13-1586","volume":"37","author":"J Woerdeman","year":"2014","unstructured":"Woerdeman J, van Duinkerken E, Wattjes MP et al (2014) Proliferative retinopathy in type 1 diabetes is associated with cerebral microbleeds, which is part of generalized microangiopathy. Diabetes Care 37:1165\u20131168. https:\/\/doi.org\/10.2337\/dc13-1586","journal-title":"Diabetes Care"},{"key":"2080_CR31","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s11739-021-02640-z","volume":"16","author":"I Cavallari","year":"2021","unstructured":"Cavallari I, Maddaloni E, Gragnano F et al (2021) Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. Intern Emerg Med 16:1583\u20131591. https:\/\/doi.org\/10.1007\/s11739-021-02640-z","journal-title":"Intern Emerg Med"},{"key":"2080_CR32","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.amjcard.2008.07.012","volume":"102","author":"G Patti","year":"2008","unstructured":"Patti G, Nusca A, Di Sciascio G (2008) Meta-analysis comparison (nine trials) of outcomes with drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol 102:1328\u20131334. https:\/\/doi.org\/10.1016\/j.amjcard.2008.07.012","journal-title":"Am J Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02080-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-022-02080-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02080-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T08:03:22Z","timestamp":1697616202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-022-02080-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2080"],"URL":"https:\/\/doi.org\/10.1007\/s00392-022-02080-5","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"assertion":[{"value":"2 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.P.: speaker or consultant fee from Astra Zeneca, Boehringer Ingelheim, Bayer, BMS, Pfizer, Daiichi Sankyo, Sanofi, Amgen, Novartis, Terumo, Abbott, Medtronic, PIAM, Chiesi, Menarini, Malesci, Servier. Grants from Astra Zeneca, Bayer, Abbott, Boston Scientific. L.P.: none. G.C.: employed by Daiichi Sankyo Italia S.p.A., Rome, Italy. M.C.M.: employed by Daiichi Sankyo Europe GmbH, Munich, Germany. P.K. was partially supported by European Union BigData@Heart (grant agreement EU IMI 116074), AFFECT-AF (grant agreement 847770), and MAESTRIA (grant agreement 965286), British Heart Foundation (PG\/17\/30\/32961; PG\/20\/22\/35093; AA\/18\/2\/34218), German Centre for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK), and Leducq Foundation. PK receives research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last 3 years. PK is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). R.D.C.: grants, speaker or consultant fee from Boehringer Ingelheim, Bayer, BMS\/Pfizer, Janssen, Daiichi Sankyo, Novartis, AstraZeneca, Milestone, Lilly, Roche, Menarini, Guidotti and Nominating Committee from European Society of Cardiology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}